Feature Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy Petros Pharmaceuticals (NASDAQ:PTPI) has set up a steering committee with the aim of applying to the FDA to make its prescription erectile dysfunction (ED) therapy, Stendra, available as an over-the-counter product in a... March 16, 2021